ARBUTUS BIOPHARMA CORP
ABUSNASDAQTrading Snapshot
- Day Range
- $4.67 – $4.78
- 52-Week Range
- $3.50 – $5.45
- Volume
- $4.56B
- Avg Volume
- $3.08B
- Shares Outstanding
- 197.5M
- Next Earnings
- Nov 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $1M
- P/E Ratio
- 6.1
- P/S Ratio
- 5.3x
- EPS (TTM)
- $0.78
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.9%
Why Investors Own ABUS
- ✓High-growth profile — revenue up +35.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ARBUTUS BIOPHARMA CORP
ABUS
StockOtter · stockotter.spaceAbout ARBUTUS BIOPHARMA CORP
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) in the second quarter, according to its most recent disclosure with the SEC. The firm pu
Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS
Bank of America Corp DE lowered its stake in Arbutus Biopharma Corporation (NASDAQ: ABUS) by 8.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institu
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plan
Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the st
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026